The FDA's Plausible Mechanism Framework Is a Beautiful Theory With No Safety Net
The FDA's new framework lets ultra-rare disease drugs win approval based on biomarkers instead of clinical trials. That sounds humane until you realize the post-market safety infrastructure to catch failures barely exists for populations this small.
By Dr. Alex Chen · 3 min read